merck p53 peptide vaccine patent peptide vaccine
merck p53 peptide vaccine patent peptide vaccine - merck-p53-peptide-patent Patents Merck's p53 Peptide Vaccine Patent: A Deep Dive into Cancer Therapy Innovation
mens-peptide-moisturizer The pursuit of effective cancer treatments has long been a central focus for pharmaceutical giants like Merck. A significant area of investigation involves the p53 protein, a critical tumor suppressor, and its potential role in therapeutic vaccines. This exploration delves into the Merck p53 peptide vaccine patent landscape, examining how Merck and other entities have sought to leverage peptides derived from or targeting p53 to combat various cancers.
The p53 protein, often referred to as the "guardian of the genome," plays a vital role in preventing uncontrolled cell proliferation. When p53 is mutated or inactivated, it can significantly contribute to cancer development. Consequently, researchers have explored strategies to restore or harness the power of p53 function.p53GeneticVaccine(NCI): a Immunostimulants Drug, Initially developed by National Cancer Institute, Now, its global highest R&D status is Discontinued, ... One such strategy involves developing p53 peptide vaccines. These vaccines aim to stimulate the immune system to recognize and attack cancer cells that express or are affected by p53 abnormalities.
Merck's involvement in this field is evident through various patent filings.EJC-138S2-ENA-2020-abstracts.pdf - EORTC Events For instance, U.S. Patent No. 8,663,646 B2, titled "P53 peptide vaccine," describes an invention related to a peptide derived from p53 that could serve as a vaccine against cancer. This aligns with the broader concept of peptide vaccines where specific fragments of disease-associated proteins are used to elicit an immune response. Another relevant patent, U.S. Patent No.2025年10月26日—Mutant p53 peptide pulsed dendritic cell vaccine(University of ... Boost your research with our Core Patent data. Clinical Trial. 9,527,896 B2, titled "Stabilized p53 peptides and uses thereof," further indicates a focus on developing and stabilizing the p53 peptides for therapeutic applications, presumably within vaccine formulations.
Beyond direct p53 vaccination, research has also focused on targeting proteins that regulate p53, such as HDM2 (Human Double Minute 2) and MDMX. By inhibiting these regulators, the activity of p53 can be enhanced.2020年7月21日—A number of companies have announced candidates for a COVID-19vaccine, including Moderna Therapeutics ($MRNA), AstraZeneca ($AZN), Johnson & Johnson ($JNJ) ... This approach is reflected in patents like "P53 activator peptidomimetic macrocycles" and "Targeted MDM2 Degradation." These peptide mimetics and degradation strategies aim to indirectly bolster p53's tumor-suppressing capabilities, offering another avenue for cancer treatment. The patent landscape also shows a keen interest in inhibiting E3 ubiquitin ligase MDM2/MDMX, which are known to inhibit p53's tumor suppressor function, thus allowing for accelerated mutation-driven cancer progressionEuropean Patent Disclosures +.
The development of p53-based vaccines is not exclusive to Merck. The patent literature reveals a broader scientific effortUS8663646B2 - P53 peptide vaccine. For example, WO 2006/124700, titled "P53 Vaccines for the Treatment of Cancers," highlights the global interest in this therapeutic area. Additionally, mutant p53 has become a focus for some research, as seen in the "Mutant p53 peptide pulsed dendritic cell vaccine" concept, suggesting a strategy to target specific, altered forms of the p53 protein. Research into targeting a neoantigen derived from a common TP53 mutation further underscores this direction.
The versatility of peptide technology extends to various vaccine platforms. The development of mRNA vaccines, as mentioned in U( 12 ) United States Patent - Googleapis.com.S.Patent Landscape of DNA VACCINES FOR HIV 2019/0008938 A1 ("Concatemeric peptide epitope rnas"), demonstrates how peptide sequences can be incorporated into novel delivery systems. Furthermore, peptide vaccines targeting tumor-associated antigens, including P53, are being explored in clinical trials, such as the randomized phase III trial referencing peptides restricted to HLA-A2 phenotype targeting tumor-associated antigens like P53.“Induction ofp53-specific immunity by ap53synthetic longpeptide vaccinein patients treated for metastatic colorectal cancer. ... https://patents.google.com/ ...
While the p53 genetic vaccine initially developed by the National Cancer Institute has seen its research status as discontinued, the underlying principles of stimulating an immune response against p53-related mechanisms continue to drive innovation. The Merck p53 peptide vaccine patent portfolio, alongside numerous other patents and research initiatives, underscores the enduring scientific and commercial interest in unlocking the therapeutic potential of p53 and peptide vaccine strategies for improved cancer treatment. The ongoing exploration of peptide inhibitors, peptide mimetics, and various vaccine modalities signifies a dynamic field with the ultimate goal of developing more effective therapies against a wide spectrum of cancersMerck seeks patents on cancer treatments, medications for ....